An effective treatment option for pain caused by urolithiasis: A randomised‐controlled trial of local active warming with heat‐patch

2021 ◽  
Author(s):  
Huseyin Mutlu ◽  
Kasim Ertas ◽  
Kamil Kokulu ◽  
Ekrem Taha Sert ◽  
Mehmet Akif Diri ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Effective Treatment ◽  
Treatment Option ◽  
Controlled Trial ◽  
Effective Treatment Option ◽  
Randomised Controlled

Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: a double-blinded, placebo-controlled randomised controlled trial

2015 ◽  
Vol 25 (6) ◽  
pp. 1830-1835
Author(s):  
S. Rajasekaran ◽  
Siddharth N. Aiyer ◽  
Ajoy Prasad Shetty ◽  
Rishi Mugesh Kanna ◽  
Anupama Maheswaran ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Treatment Option ◽  
Cervical Myelopathy ◽  
Controlled Trial ◽  
Randomised Controlled ◽  
Double Blinded

scholarly journals Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

2021 ◽  
Author(s):  
Sanjay Ramakrishnan ◽  
Dan V. Nicolau ◽  
Beverly Langford ◽  
Mahdi Mahdi ◽  
Helen Jeffers ◽  
...  
Keyword(s):  
Health Care ◽  
Emergency Department ◽  
Randomised Controlled Trial ◽  
Usual Care ◽  
Effective Treatment ◽  
Controlled Trial ◽  
Urgent Care ◽  
Open Label ◽  
Inhaled Budesonide ◽  
Randomised Controlled

AbstractBackgroundMultiple early hospital cohorts of coronavirus disease 2019 (COVID-19) showed that patients with chronic respiratory disease were significantly under-represented. We hypothesised that the widespread use of inhaled glucocorticoids was responsible for this finding and tested if inhaled glucorticoids would be an effective treatment for early COVID-19 illness.MethodsWe conducted a randomised, open label trial of inhaled budesonide, compared to usual care, in adults within 7 days of the onset of mild Covid-19 symptoms. The primary end point was COVID-19-related urgent care visit, emergency department assessment or hospitalisation. The trial was stopped early after independent statistical review concluded that study outcome would not change with further participant enrolment.Results146 patients underwent randomisation. For the per protocol population (n=139), the primary outcome occurred in 10 participants and 1 participant in the usual care and budesonide arms respectively (difference in proportion 0.131, p=0.004). The number needed to treat with inhaled budesonide to reduce COVID-19 deterioration was 8. Clinical recovery was 1 day shorter in the budesonide arm compared to the usual care arm (median of 7 days versus 8 days respectively, logrank test p=0.007). Proportion of days with a fever and proportion of participants with at least 1 day of fever was lower in the budesonide arm. Fewer participants randomised to budesonide had persistent symptoms at day 14 and day 28 compared to participants receiving usual care.ConclusionEarly administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery following early COVID-19 infection.(Funded by Oxford NIHR Biomedical Research Centre and AstraZeneca; ClinicalTrials.gov number, NCT04416399)Research in contextEvidence before this studyThe majority of interventions studied for the COVID-19 pandemic are focused on hospitalised patients. Widely available and broadly relevant interventions for mild COVID-19 are urgently needed.Added value of this studyIn this open label randomised controlled trial, inhaled budesonide, when given to adults with early COVID-19 illness, reduces the likelihood of requiring urgent care, emergency department consultation or hospitalisation. There was also a quicker resolution of fever, a known poor prognostic marker in COVID-19 and a faster self-reported and questionnaire reported symptom resolution. There were fewer participants with persistent COVID-19 symptoms at 14 and 28 days after budesonide therapy compared to usual care.Implications of all the available evidenceThe STOIC trial potentially provides the first easily accessible effective intervention in early COVID-19. By assessing health care resource utilisation, the study provides an exciting option to help with the worldwide pressure on health care systems due to the COVID-19 pandemic. Data from this study also suggests a potentially effective treatment to prevent the long term morbidity from persistent COVID-19 symptoms.

Filmed versus Live Social Contact Interventions to Reduce Stigma: A Randomised Controlled Trial

2012 ◽  
Author(s):  
Sarah Clement ◽  
Adrienne van Nieuwenhuizen ◽  
Aliya Kassam ◽  
Ian Norman ◽  
Clare Flach ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Social Contact ◽  
Randomised Controlled
Sign in / Sign up

Export Citation Format

Share Document